Nektar Therapeutics

Other

Ute Hoch

Deborah H Charych

Stephen David Harrison

Michael A Eldon

Dennis G Fry

Alison Hannah

Christine Taylor Brew

Nancy Marie Burns

Yen Lin Chia

Darren W Davis

Abraham C F Leung

The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.

Combination-based treatment method

Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.

Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor

Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.

Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents

Growing community of inventors

San Francisco, CA, United States of America

Ute Hoch